Concord Drugs Profit & Loss Annual

BSE: - | NSE: - | ISIN: - | Sector: -

86.00 +3.61 (4.38%)Updated : 17 Apr 2026

Interim Data

Annual Data

Fiscal Period	2025	2024	2023	2022
Period End Date	Mar 25	Mar 24	Mar 23	Mar 22
Total Operating Expense	42.54	42.44	49.13	55.13
Other Net	-0.09	-0.04	-0.06	-0.17
Diluted Weighted Average Shares	1.00	1.00	0.93	0.87
Depreciation/ Amortization	1.43	1.56	1.63	1.76
Operating Income	2.70	2.49	2.95	3.83
Net Income	0.34	0.47	0.99	1.59
Income Availableto Com Excl Extra Ord	0.34	0.47	0.99	1.59
Net Income Before Taxes	0.69	0.63	1.25	2.25
Other Operating Expenses Total	1.25	1.55	1.59	6.37
Net Income After Taxes	0.34	0.47	0.99	1.59
Income Availableto Com Incl Extra Ord	0.34	0.47	0.99	1.59
Costof Revenue Total	35.23	33.25	41.00	42.10
Gross Profit	10.01	11.67	11.08	16.86
Interest Inc( Exp) Net- Non- Op Total	-1.92	-1.82	-1.63	-1.41
Diluted Net Income	0.34	0.47	0.99	1.59
Provisionfor Income Taxes	0.36	0.16	0.26	0.65
period Type	-	-	-	-
Net Income Before Extra Items	0.34	0.47	0.99	1.59
Total Revenue	45.24	44.92	52.08	58.96
period Length	12.00	12.00	12.00	12.00
Revenue	45.24	44.92	52.08	58.96
Selling/ General/ Admin Expenses Total	4.63	6.08	4.92	4.89
Diluted Normalized EPS	0.34	0.47	1.06	1.82
Diluted EPS Excluding Extra Ord Items	0.34	0.47	1.06	1.82
Unusual Expense( Income)	-	-	0.00	0.00